BMYMirati Therapeutics Inc.Running, no new patients
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Advanced Cancer · Metastatic Cancer · Malignant Neoplastic Disease
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 731 (final count)
- Started
- Jan 15, 2019
- Main results expected
- Jun 23, 2026
- Fully finished
- Dec 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation
Measured over: 20 months
Evaluate the pharmacokinetics of MRTX849
Measured over: 20 months
Evaluate clinical activity/efficacy of MRTX849
Measured over: 20 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03785249 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC